News Releases

News Category

Year

03 Mar '2020

Advaxis to Present at the 2020 LD Micro Virtual Conference

PRINCETON, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin , President and Chief Executive Officer of Advaxis will

PDF Version

27 Feb '2020

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response observed in one patient and the other patient achieved stable disease with a 25% reduction in a target

PDF Version

20 Feb '2020

Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable disease with a 25% reduction in a site lesion in combination arm PRINCETON, N.J.

PDF Version

13 Feb '2020

Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA ® compared to an estimated 11 months with Standard of Care Median overall survival of 33.7 months in all patients treated with ADXS-PSA in

PDF Version

11 Feb '2020

Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

PRINCETON, N.J. and MENLO PARK, Calif. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer,

PDF Version

30 Jan '2020

Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings

PRINCETON, N.J. , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the following upcoming presentations at medical meetings: ASCO - Genitourinary Cancers

PDF Version

21 Jan '2020

Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

PRINCETON, N.J. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into a definitive agreement with two institutional

PDF Version

07 Jan '2020

Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer

ADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA PRINCETON, N.J. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy

PDF Version

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 18 of 18